SCIENTIFIC HUB

Follow the evidence.

SCIENTIFIC LITERATURE · MED

The effect of levodopa on speech graphs in non-demented patients with multiple system atrophy and Parkinson's disease.

Front Neurol · 2026-02-09

DOI: 10.3389/fneur.2026.1746101PMID: 41738003

Open accessresearch-article; Journal ArticleOriginal source ↗

Research overview

The text below is the source article’s original abstract under a verified reuse license. cc by

BackgroundAn objective topological analysis for any arbitrary network was provided by graph theory, which was implemented to reveal topological properties of brain networks in a wide range of neurodegenerative diseases.ObjectivesTo investigate the difference of the topology of speech graphs among parkinsonian-type multiple system atrophy patients (MSA-P), idiopathic Parkinson's disease (PD) patients, and healthy controls (HC). To explore the effect of levodopa on the topology of speech graphs in MSA-P and PD patients.MethodsWe applied a graph analysis of topology of speech graphs in MSA-P patients (N = 39), idiopathic PD patients (N = 51), and HC (N = 51). All participants were assessed by a well-established semantic fluency test (animal). Participants' verbal reactions were listed and represented as speech graphs with directionality.ResultsMSA-P patients mentioned more about their memory and remaining time than PD patients (p p p = 0.004; HC: p p = 0.007; HC: p p = 0.004; HC: p p = 0.002; HC: p r = 0.39, p = 0.017) and average shortest path (r = 0.38, p = 0.017) were obtained, suggesting that higher levodopa doses were associated with producing sparser and larger speech graphs in MSA-P patients. However, there was no significant correlation between levodopa equivalent daily dose and graph indices in PD patients.ConclusionMSA-P patients' speech graphs were denser and smaller than both PD patients and healthy adults. The graph analysis of semantic fluency can differentiate MSA-P from PD to some extent. Importantly, in MSA-P patients, the impaired speech topology can be partially restored by levodopa.

Scientific assessment

01

Research question

Assess the question within the original study’s scope.

02

Methods & sample

Check the source article for study design and sample details.

03

Key findings

An editorially approved findings summary is not yet published for this record.

04

Limitations

Generalizability, bias and clinical meaning require separate assessment.

Methods, samples and clinical conclusions are not inferred from bibliographic metadata.